|
 

Recall of Migraine Injection Needles

The Medicines and Healthcare products Regulatory Agency (MHRA) today issued a drug alert to pharmacies, dispensing clinics and wholesalers asking them to return some stocks to their original supplier of an injection used to relieve acute migraines - Imigran Injection/Subject.

 

This follows a recall by GlaxoSmithKline UK for five batches of the medicine due to a manufacturing fault causing a small number of needles to protrude from the protective shield.

Adam Burgess, MHRA Manager of the Defective Medicines Recall Centre (DMRC) said:

This is not a recall to patient level as the number of needles affected is thought to be very small and the risk to members of the public finding an affected syringe is extremely low. There is, however, a slight risk of infection from an unprotected needle and we would ask people to take extra care when using these syringes.

The affected batch numbers are:

  • Imigran Inj/ Subject Treatment C640404, C638748, C636954
  • Imigran Inj / Subject Treatment Refill C639899, C638737

Link to drug alert

 

 

 

qr code

 
 
About The Operating Theatre Journal

The Operating Theatre Journal, OTJ, is published monthly and distributed to every hospital operating theatre department in the UK. The distribution includes both the National Health Service and the Private Sector.

More »
Follow & Share

Follow The Operating Theatre Journal on Facebook Follow The Operating Theatre Journal on Twitter Follow The Operating Theatre Journal on LinkedIn Follow The Operating Theatre Journal RSS Feed

Help & Support

Problems with, or comments about, this website may be emailed to:
webmaster@lawrand.com

Get in touch

Telephone: +44 (0)2921 680068
Skype: Lawrand Ltd
Email: admin@lawrand.com